3-Feb-2026
Business Wire (Thu, 29-Jan 7:30 AM ET)
Organon Completes Divestiture of JADA System to Laborie
Business Wire (Wed, 28-Jan 12:45 PM ET)
Market Chameleon (Tue, 20-Jan 6:45 AM ET)
Business Wire (Fri, 16-Jan 9:12 PM ET)
Business Wire (Thu, 8-Jan 1:30 AM ET)
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
Business Wire (Tue, 25-Nov 7:30 AM ET)
Organon Gains Strategic Edge with FDA Approval of First PERJETA Biosimilar POHERDY
Market Chameleon (Mon, 17-Nov 3:41 AM ET)
Business Wire (Mon, 17-Nov 5:30 AM ET)
Business Wire (Fri, 14-Nov 6:37 PM ET)
Adjusted Profitability Improves at Organon as Cost Controls Offset Modest Revenue Growth
Market Chameleon (Mon, 10-Nov 3:12 AM ET)
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Organon & Co. Common trades on the NYSE stock market under the symbol OGN.
As of February 3, 2026, OGN stock price declined to $8.00 with 4,248,873 million shares trading.
OGN has a beta of 0.49, meaning it tends to be less sensitive to market movements. OGN has a correlation of 0.02 to the broad based SPY ETF.
OGN has a market cap of $2.08 billion. This is considered a Mid Cap stock.
Last quarter Organon & Co. Common reported $2 billion in Revenue and $1.01 earnings per share. This beat revenue expectation by $29 million and exceeded earnings estimates by $.09.
In the last 3 years, OGN traded as high as $29.88 and as low as $6.18.
The top ETF exchange traded funds that OGN belongs to (by Net Assets): IJR, VTI, VB, VBR, FXH.
OGN has underperformed the market in the last year with a price return of -44.1% while the SPY ETF gained +16.6%. However, in the short term, OGN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +19.5% vs +1.2% return in SPY. But in the last 2 weeks, OGN shares have been beat by the market, returning -15.4% compared to an SPY return of +1.8%.
OGN support price is $7.88 and resistance is $8.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OGN shares will trade within this expected range on the day.
